Abstract
We have developed a competitive ELISA using a polyclonal antibody that showed specificity to both metallothionin (MT)-1 and MT-2 isoforms in human and animal specimens. The advantage of this ELISA depends on the characteristics of the polyclonal antibody. The NH2 terminal peptide of MT with acetylated methionine was shown to be the epitope of this antibody. The reactivity of this ELISA system with liver, kidney, and brain extracts worked very well for MT1,2 in wild type mice. Extracts of MT-3 knock-out mice also react well this ELISA, as expected, very low in MT 1,2 but in MT1/2 knock-out mice. Detection limits, the ranges of linearity, and reliability coefficients of MT quantification of the ELISA were suitable for determination of MT. From the preliminary study of normal reference ranges, we found that normal MT levels were between approximately 10-30 ng/ml in human serum. We expect in the future to detect cases with low (MT deficiency) and high serum MT concentrations in patients with various diseases, such as brain/liver disorders, and cancers, using this MT ELISA.
Keywords: Acetylated methionine residue, competitive enzyme-linked immunosorbent assay, epitope mapping, metallothionein, metallothionein-null mouse, metallothionein isoforms.
Current Pharmaceutical Biotechnology
Title:Development of a High Sensitivity ELISA for the Assay of Metallothionein
Volume: 14 Issue: 4
Author(s): Takeaki Nagamine and Katsuyuki Nakajima
Affiliation:
Keywords: Acetylated methionine residue, competitive enzyme-linked immunosorbent assay, epitope mapping, metallothionein, metallothionein-null mouse, metallothionein isoforms.
Abstract: We have developed a competitive ELISA using a polyclonal antibody that showed specificity to both metallothionin (MT)-1 and MT-2 isoforms in human and animal specimens. The advantage of this ELISA depends on the characteristics of the polyclonal antibody. The NH2 terminal peptide of MT with acetylated methionine was shown to be the epitope of this antibody. The reactivity of this ELISA system with liver, kidney, and brain extracts worked very well for MT1,2 in wild type mice. Extracts of MT-3 knock-out mice also react well this ELISA, as expected, very low in MT 1,2 but in MT1/2 knock-out mice. Detection limits, the ranges of linearity, and reliability coefficients of MT quantification of the ELISA were suitable for determination of MT. From the preliminary study of normal reference ranges, we found that normal MT levels were between approximately 10-30 ng/ml in human serum. We expect in the future to detect cases with low (MT deficiency) and high serum MT concentrations in patients with various diseases, such as brain/liver disorders, and cancers, using this MT ELISA.
Export Options
About this article
Cite this article as:
Nagamine Takeaki and Nakajima Katsuyuki, Development of a High Sensitivity ELISA for the Assay of Metallothionein, Current Pharmaceutical Biotechnology 2013; 14 (4) . https://dx.doi.org/10.2174/1389201011314040007
DOI https://dx.doi.org/10.2174/1389201011314040007 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Transport Mechanisms at the Blood-Cerebrospinal-Fluid Barrier: Role of Megalin (LRP2)
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Recent Advances in Clarifying Prion Protein Functions Using Knockout Mice and Derived Cell Lines
Mini-Reviews in Medicinal Chemistry Using Endogenous Neural Stem Cells to Enhance Recovery from Ischemic Brain Injury
Current Neurovascular Research Intrathecal Administration of Melatonin Ameliorates the Neuroinflammation- Mediated Sensory and Motor Dysfunction in A Rat Model of Compression Spinal Cord Injury
Current Molecular Pharmacology Aquaretic Agents: Whats Beyond the Treatment of Hyponatremia?
Current Pharmaceutical Design Potential Protective Effect of Dl-3-n-butylphthalide on Chronic Cerebral Ischemia Brain Injury
CNS & Neurological Disorders - Drug Targets Hyperglycemia, Hypoglycemia and Dementia: Role of Mitochondria and Uncoupling Proteins
Current Molecular Medicine A Review of Agents Patented for their Neuroprotective Properties
Recent Patents on CNS Drug Discovery (Discontinued) Endocannabinoid Regulation of Matrix Metalloproteinases: Implications in Ischemic Stroke
Cardiovascular & Hematological Agents in Medicinal Chemistry Mitochondrial Encephalomyopathies in Children. Part II: Advanced MR Tools and the Importance for its Early Recognition in the Acute Clinical Setting
Current Medical Imaging Small Molecular Weight Inhibitors of Stress-Activated and Mitogen- Activated Protein Kinases
Mini-Reviews in Medicinal Chemistry Innate Immune Surveillance in the Central Nervous System Following Legionella pneumophila Infection
CNS & Neurological Disorders - Drug Targets The Cholinergic Potential, the Vagus Nerve and Challenges in Treatment of Traumatic Brain Injury
Current Pharmaceutical Design Matrix Metalloproteinase Knockout Studies and the Potential Use of Matrix Metalloproteinase Inhibitors in the Rheumatic Diseases
Current Drug Targets - Inflammation & Allergy Wound Healing Agents: The Role of Natural and Non-Natural Products in Drug Development
Mini-Reviews in Medicinal Chemistry A Review on Natural Sources Derived Protein Nanoparticles as Anticancer Agents
Current Topics in Medicinal Chemistry Borna Disease Virus (BDV): Neuropharmacological Effects of a CNS Viral Infection
Current Neuropharmacology Pleiotropic Actions of PPARg Activators Thiazolidinediones in Cardiovascular Diseases
Current Pharmaceutical Design Imaging of Wallerian Degeneration in the Brain
Current Medical Imaging Pharmacological Therapy of Cushings Syndrome: Drugs and Indications
Mini-Reviews in Medicinal Chemistry